Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
SpringWorks Therapeutics Inc Market Cap
From what 0 stock analysts predict, the share price for SpringWorks Therapeutics Inc (SWTX) might increase by 90.71% in the next year. This is based on a 12-month average estimation for SWTX. Price targets go from $58 to $80. The majority of stock analysts believe SWTX is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assignedSWTX 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect SpringWorks Therapeutics Inc to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on SWTX. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of SWTX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Anupam Rama JP Morgan | Overweight | $68 | Maintains | Sep 4, 2024 |
| Robert Burns HC Wainwright & Co. | Buy | $76 | Reiterates | Aug 28, 2024 |
| Robert Burns HC Wainwright & Co. | Buy | $74 | Reiterates | Jun 4, 2024 |
| Robert Burns HC Wainwright & Co. | Buy | $74 | Reiterates | May 31, 2024 |
| Robert Burns HC Wainwright & Co. | Buy | $74 | Reiterates | May 6, 2024 |
| Robert Burns HC Wainwright & Co. | Buy | $74 | Maintains | Mar 6, 2024 |
| Anupam Rama JP Morgan | Overweight | $75 | Maintains | Mar 6, 2024 |
| Peter Lawson Barclays | Overweight | $63 | Maintains | Feb 29, 2024 |
| David Nierengarten Wedbush | Outperform | $70 | Maintains | Feb 26, 2024 |
| Peter Lawson Barclays | Overweight | $47 | Maintains | Jan 25, 2024 |
| Robert Burns HC Wainwright & Co. | Buy | $73 | Maintains | Nov 29, 2023 |
| Corinne Jenkins Goldman Sachs | Buy | $52 | Maintains | Nov 29, 2023 |
| Robert Burns HC Wainwright & Co. | Buy | $64 | Maintains | Nov 28, 2023 |
| Robert Burns HC Wainwright & Co. | Buy | $52 | Maintains | Nov 20, 2023 |
| Robert Burns HC Wainwright & Co. | Buy | $58 | Maintains | Nov 9, 2023 |
| Robert Burns HC Wainwright & Co. | Buy | $66 | Reiterates | Aug 24, 2023 |
HC Wainwright & Co. | Buy | Maintains | Aug 7, 2023 | |
| Corinne Jenkins Goldman Sachs | Buy | $49 | Maintains | Jul 20, 2023 |
| Robert Burns HC Wainwright & Co. | Buy | $105 | Reiterates | Jun 6, 2023 |
| Robert Burns HC Wainwright & Co. | Buy | $105 | Reiterates | May 5, 2023 |
When did it IPO
2019
Staff Count
305
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Saqib Islam J.D.
Market Cap
$2.78B
In 2023, SWTX generated $5.4M in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that SWTX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Fri, 06 Sep 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - SpringWorks Therapeutics (SWTX) reported earnings 30 days ago; investors should monitor upcoming developments and market reactions for potential stock movement.
Why It Matters - Earnings reports can impact stock prices significantly. Investors assess financial performance and future prospects, influencing their buy, hold, or sell decisions for SpringWorks Therapeutics.
Thu, 05 Sep 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Analysts' price targets for SpringWorks Therapeutics (SWTX) suggest a 61.1% upside, supported by a consensus on increasing earnings estimates.
Why It Matters - Analysts' price targets suggest significant upside potential for SpringWorks Therapeutics, indicating confidence in future earnings growth, which could attract investor interest.
Thu, 29 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - The FDA has accepted and granted priority review to SpringWorks' NDA for mirdametinib, targeting neurofibromatosis type 1-associated plexiform neurofibromas.
Why It Matters - FDA acceptance and priority review of mirdametinib increases the likelihood of market approval, potentially boosting SpringWorks' stock value and attracting investor interest.
Wed, 28 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - SpringWorks Therapeutics' NDA for mirdametinib to treat NF1-PN has been accepted by the FDA, with a PDUFA date of February 28, 2025. The EU EMA also validated its marketing application.
Why It Matters - The FDA's acceptance of SpringWorks' NDA and the PDUFA date increase the likelihood of mirdametinib's approval, potentially boosting the company's market value and revenue prospects.
Fri, 23 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Investing in SpringWorks (SWTX) stock is being considered prudent due to multiple favorable factors, though specific reasons were not detailed in the excerpt.
Why It Matters - Potential investment in SpringWorks (SWTX) may indicate favorable market conditions or growth opportunities, suggesting possible returns for investors.
Tue, 20 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Analysts' price targets for SpringWorks Therapeutics (SWTX) suggest a 77.9% upside, supported by a consensus in raised earnings estimates.
Why It Matters - Analysts' price targets suggesting a 77.9% upside and consensus on rising earnings estimates signal potential growth for SpringWorks Therapeutics, attracting investor interest.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
